Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is to regain compliance with Nasdaq listing requirements.
The Company's common stock is expected to begin trading on a split-adjusted basis on August 18, 2025.
Purpose of Reverse Split
To maintain listing compliance on the Nasdaq Capital Market.
Impact on Shares
Outstanding shares reduced from approximately 4.77 million to 1.59 million.
Fractional Shares
No fractional shares will be issued, and cash will be given in lieu of fractions.
CEO's Statement
Richard Paolone sees the split as a crucial step to enhance shareholder value.
- The reverse stock split aims to improve the company's visibility and credibility on the Nasdaq market.
- Reducing outstanding shares may impact trading dynamics and market perception of Entero Therapeutics, Inc.
Entero Therapeutics, Inc.'s reverse stock split reflects a strategic move to meet Nasdaq compliance requirements and enhance shareholder value. The decision signals the company's commitment to long-term growth and market positioning.